Year: 2025

AB “Ignitis grupė” (hereinafter – the Group) informs that the Group’s Supervisory Board has made a decision to initiate a public selection process for the new Management Board, given that the term of office of the Group’s current Management Board (hereinafter – the Management Board) is approaching its end. The new Management Board would take office by 25 March 2026. Candidates are welcome to apply until 5 January 2026 (inclusive). Job advertisements and qualification requirements for candidates are available on the Group’s website:Link to the position of Chair of the Management Board and CEO: (link) Link to the Management Board competency profiles for People & Business Support (Group Chief Organisational Development Officer), Finance (Group Chief Financial Officer), Energy Markets & Commerce (Group Chief Commercial Officer),...

AB “Ignitis grupė” (hereinafter – the Group) informs that the Group’s Supervisory Board has made a decision to initiate a public selection process for the new Management Board, given that the term of office of the Group’s current Management Board (hereinafter – the Management Board) is approaching its end. The new Management Board would take office by 25 March 2026. Candidates are welcome to apply until 5 January 2026 (inclusive). Job advertisements and qualification requirements for candidates are available on the Group’s website:Link to the position of Chair of the Management Board and CEO: (link) Link to the Management Board competency profiles for People & Business Support (Group Chief Organisational Development Officer), Finance (Group Chief Financial Officer), Energy Markets & Commerce (Group Chief Commercial Officer),...

STOCKHOLM, Sweden, December 11, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented new preclinical data on its immunotherapy SVF-001, targeting hepatitis B and D, as a late-breaking abstract at the HepDart scientific meeting held December 7-11 in Honolulu, Hawaii. The results are follow-up data from a previously reported study, showing extended antiviral effect in preclinical models. SVF Vaccines develops DNA vaccines and immunotherapies based on proprietary technology originating from Karolinska Institutet. New data from the SVF-001 preclinical program demonstrate apparent antiviral activity of the antibody treatment up to six weeks after treatment. The data on the extended effect are based on a follow-up analysis in a previously reported preclinical study, showing...

Tallinna Vesi signed a €25 million loan agreement with the Nordic Investment Bank (NIB) to finance investments in 2025–2026. Tallinna Vesi’s investments will total €60 million in both 2025 and 2026, in line with the company’s strategy and the objectives set out in the Tallinn Public Water Supply and Sewerage Development Plan. These investments are intended to reduce the environmental footprint and increase cost efficiency. “This agreement will help us implement our investment plan and ensure the high quality and sustainability of our water services while maintaining a clean natural environment. These investments will support us on our environmental journey which was recently recognised when we received the Estonian Green Company of the Year award,” said Taavi Gröön, CFO of Tallinna Vesi. The loan from the Nordic Investment...

Sampo plc, stock exchange release, 11 December 2025 at 8:30 am EET Sampo plc’s share buybacks 10 December 2025 On 10 December 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  4,807 10.04 AQEU    118,843 10.04 CEUX  27,929 10.04 TQEX  108,644 10.04 XHELTOTAL 260,223 10.04  * rounded to two decimals                      On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November...

US market activity and, as a result, order intake in Nilfisk’s US business has not improved as expected in November and the beginning of December. In addition, short-term issues with one supplier have limited the capacity to ship full volume of two products, before year-end. As a result, Nilfisk now expects organic growth for 2025 in the range of 0–1%. Nilfisk continues to expect an EBITDA margin before special items of 13%-14% including profit contribution from associates.   New outlookDecember 11, 2025 Previous outlookNovember 20, 2025Organic revenue growth 0% to 1%   Around                1%EBITDA margin before special items 13%-14% 13% to 14%Contact Nynne Jespersen Lee, Head of IR & Group Communications, +45 4231 0007 Forward-looking statements Statements made about the future in this report reflect the Executive Management...

Funding to provide runway through potential Graves’ Disease commercial launchNEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transaction. Roivant Sciences Ltd., the Company’s controlling stockholder, has agreed to purchase shares in the offering. All of the shares are to be sold by Immunovant. Immunovant currently expects that its existing cash and cash equivalents, together with the proceeds from the transaction, will be...

November was characterised by growth in strategic loan products and term deposits, a decrease in the share of non-performing loans, and satisfactory profitability. The loan portfolio grew by 25 million euros during the month, reaching 2.6 billion euros by the end of November. Growth was driven by business loans, which increased by 33 million euros, and home loans, which grew by 14 million euros. The consumer loan portfolio decreased by 22 million euros. A significant part of this decline was due to the sale of the entire loan portfolio of the Swedish branch to another Swedish credit institution on 6 November 2025. As a result of the transaction, Bigbank’s Swedish branch will continue to operate solely as a deposit-taking entity. The deposit portfolio increased by 32 million euros in November. Deposit interest rates have started to rise...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright & Co.”) initially entered into on January 30, 2024. The at-the-market offering program enables Addex to offer and sell, from time to time at its sole discretion, ADSs having an aggregate offering price of up to $3.3 million through H.C. Wainwright & Co., as its sales agent. The issuance and sale, if any, of the ADSs by the Company under the ATM Agreement will be made pursuant to the Company’s effective...